Benzinga | Mar 11, 2021 07:35AM EST

Biohaven's NURTEC ODT Approved In United Arab Emirates For Acute Treatment Of Migraine

- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel

- NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)

- A single oral dose of NURTEC ODT 75 mg can provide fast pain relief and return patients to normal function within 60 minutes, and deliver sustained efficacy that lasts up to 2 days for many patients